Last reviewed · How we verify
DOAC
DOAC, marketed by Insel Gruppe AG and University Hospital Bern, holds a position in the anticoagulant market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the strong intellectual property protection. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | DOAC |
|---|---|
| Also known as | Direct Oral Anti Coagulants, Rivaroxaban, Apixiban, Dabigatran, Edoxaban |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. (PHASE3)
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOAC CI brief — competitive landscape report
- DOAC updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI